5-HT7 receptor modulators: A medicinal chemistry survey of recent patent literature (2004 - 2009)

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 6, 2010, Pages 739-754

  Leopoldo, Marcello ^a   Lacivita, Enza ^a   Berardi, Francesco ^a   Perrone, Roberto ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

AS 19; Circadian rhythm; CNS; Depression; GPCRs; Medicinal chemistry; Pain; SB 269970; Serotonin 5 HT7 receptor; Structureactivity relationships

Indexed keywords

2 AMINOTETRALIN DERIVATIVE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,2A,4,5 TETRAHYDRO 1H 3 AZAACENETHYLENE DERIVATIVE; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; AMISULPRIDE; AS 19; CITALOPRAM; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SB 258741; SB 278519; SB 656104; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SULFONAMIDE; UNCLASSIFIED DRUG; VILAZODONE;

ALLODYNIA; ANTINOCICEPTION; CLINICAL TRIAL; DEPRESSION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSTHYMIA; HUMAN; MAJOR DEPRESSION; MIGRAINE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATENT; RECEPTOR BLOCKING; REM SLEEP; REVIEW; SCHIZOPHRENIA; SPATIAL MEMORY; STRUCTURE ACTIVITY RELATION; SUPRACHIASMATIC NUCLEUS; TRANQUILIZING ACTIVITY;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; RATS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 77952567083     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.484802     Document Type: Review

References (85)

1. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994;46:157-203
2. Vanhoenacker P, Haegeman G, Leysen JE. 5-HT7 receptors: current knowledge and future prospects. Trends Pharmacol Sci 2000;21:70-77
3. Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 2004;25:481-486
4. To ZP, Bonhaus DW, Eglen RM, et al. Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain. Br J Pharmacol 1995;115:107-116
5. Mengod G, Vilaro MT, Raurich A, et al. 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochem J 1996;28:747-758
6. Waeber C, Moskowitz MA. Autoradiographic visualisation of [3H]5-carboxamidotryptamine binding sites in the guinea pig and rat brain. Eur J Pharmacol 1995;283:31-46
7. Gustafson EL, Durkin MM, Bard JA, et al. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-ht7 receptor in rat brain. Br J Pharmacol 1996;117:657-666
8. Bonaventure P, Nepomuceno D, Hein L, et al. Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine7 receptor distribution and uncovers 8-hydroxy-2- (di-n-propylamino)tetralin interaction with alpha2 adrenergic receptors. Neuroscience 2004;124:901-911
9. Varnäs K, Thomas DR, Tupala E, et al. Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H] SB-269970. Neurosci Lett 2004;367:313-316
10. Neumaier JF, Sexton TJ, Yracheta J, et al. Localization of 5-HT7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. J Chem Neuroanat 2001;21:63-73
11. Belenky MA, Pickard GE. Subcellular distribution of 5-HT1B and 5-HT7 receptors in the mouse suprachiasmatic nucleus. J Comp Neurol 2001;432:371-388
12. Doly S, Fischer J, Brisorgueil MJ, et al. Pre- and postsynaptic localization of the 5-HT7 receptor in rat dorsal spinal cord: immunocytochemical evidence. J Comp Neurol 2005;490:256-269
13. Hagan JJ, Price GW, Jeffrey P, et al. Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. Br J Pharmacol 2000;130:539-548
14. Hedlund PB, Danielson PE, Thomas EA, et al. No hypothermic response to serotonin in 5-HT7 receptor knockout mice. Proc Natl Acad Sci USA 2003;100:1375-1380
15. Guscott M, Bristow LJ, Hadingham K, et al. Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology 2005;48:492-502
16. Sprouse J, Li X, Stock J, et al. Circadian rhythm phenotype of 5-HT7 receptor knockout mice: 5-HT and 8-OH-DPATinduced phase advances of SCN neuronal firing. J Biol Rhythms 2005;20:122-131
17. Witkin JM, Baez M, Yu J, et al. Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholds. Epilepsy Res 2007;75:39-45
18. Hedlund PB, Sutcliffe JG. 5-HT7 receptors as favorable pharmacological targets for drug discovery. In: Roth BL, editor, The serotonin receptors: from molecular pharmacology to human therapeutics Humana Press, Totowa, NJ; 2006. p. 517-535
19. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009;206:345-354
20. Monsma FJ, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320-327
21. Mullins UL, Gianutsos G, Eison AS. Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology 1999;21:352-367
22. Hedlund PB, Huitron-Resendiz S, Henriksen SJ. 5-HT7 receptor inhibition and inactivation induce antidepressant like behavior and sleep pattern. Biol Psychiatry 2005;58:831-837
23. Wesolowska A, Nikiforuk A, Stachowicz K, et al. Effect of the selective 5-HT7 receptor antagonist SB-269970 in animal models of anxiety and depression. Neuropharmacology 2006;51:578-586
24. Wesolowska A, Nikiforuk A, Stachowicz K. Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB-269970 after intrahippocampal administration to rats. Eur J Pharmacol 2006;553:185-190
25. Wesolowska A, Tatarczynska E, Nikiforuk A, et al. Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur J Pharmacol 2007;555:43-47
26. Bonaventure P, Kelly L, Aluisio L. Selective blockade of 5-hydroxytryptamine 5-HT7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther 2007;321:690-698
27. Antle MC, Ogilvie MD, Pickard GE, et al. Response of the mouse circadian system to serotonin 1A/2/7 agonists in vivo: surprisingly little. J Biol Rhythms 2003;18:145-148
28. Glass JD, Grossman GH, Farnbauch L, et al. Midbrain raphe modulation of nonphotic circadian clock resetting and 5-HT release in the mammalian suprachiasmatic nucleus. J Neurosci 2003;23:7451-7460
29. Duncan MJ, Short J, Wheeler DL. Comparison of the effects of aging on 5-HT7 and 5-HT1A receptors in discrete regions of the circadian timing system in hamsters. Brain Res 1999;829:39-45
30. Sprouse J, Reynolds L, Li X, et al. 8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology 2004;46:52-62
31. Lovenberg TW, Baron BM, de Lecea L, et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993;11:449-458
32. Ehlen JC, Grossman GH, Glass JD. In vivo resetting of the hamster circadian clock by 5-HT7 receptors in the suprachiasmatic nucleus. J Neurosci 2001;21:5351-5357
33. Ying SW, Rusak B. 5-HT7 receptors mediate serotonergic effects on light-sensitive suprachiasmatic nucleus neurons. Brain Res 1997;755:246-254
34. Yu GD, Liu YL, Jiang XH, et al. The inhibitory effect of serotonin on the spontaneous discharge of suprachiasmatic neurons in hypothalamic slice is mediated by 5-HT7 receptor. Brain Res Bull 2001;54:395-398
35. Gardani M, Biello S. The effects of photic and nonphotic stimuli in the 5-HT7 receptor knockout mouse. Neuroscience 2008;152:245-253
36. Thomas DR, Melotto S, Massagrande M, et al. SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol 2003;139:705-714
37. Roberts AJ, Krucker T, Levy CL, et al. Mice lacking 5-HT7 receptors show specific impairments in contextual learning. Eur J Neurosci 2004;19:1913-1922
38. Sarkisyan G, Hedlund PB. The 5-HT7 receptor is involved in allocentric spatial memory information processing. Behav Brain Res 2009;202:26-31
39. Perez-Garc?́a GS, Meneses A. Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task. Behav Brain Res 2005;163:136-140
40. Johnson KW, Schaus JM, Durkin MM, et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997;8:2237-2240
41. Ullmer C, Schmuck K, Kalkman HO, et al. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett 1995;370:215-221
42. Schoeffter P, Ullmer C, Bobirnac I, et al. Functional, endogenously expressed 5-hydroxytryptamine 5-HT7 receptors in human vascular smooth muscle cells. Br J Pharmacol 1996;117:993-994
43. Verheggen R, Meier A, Werner I, et al. Functional 5-HT receptors in human occipital artery. Naunyn Schmiedebergs Arch Pharmacol 2004;369:391-401
44. Terrón JA, Falcón-Neri A. Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral artery. Br J Pharmacol 1999;127:609-616
45. Villalon CM, Centurion D, Lujan-Estrada M, et al. Mediation of 5-HT-induced external carotid vasodilatation in GR 127935-pretreated vagosympathectomized dogs by the putative 5-HT7 receptor. Br J Pharmacol 1997;120:1319-1327
46. Terrón JA, Mart?́nez-Garc?́a E. 5-HT7 receptor-mediated dilatation in the middle meningeal artery of anesthetized rats. Eur J Pharmacol 2007;560:56-60
47. Mart?́nez-Garc?́a E, Garc?́a-Iglesias B, Terrón JA. Effect of central serotonin depletion on 5-HT receptor-mediated vasomotor responses in the middle meningeal artery of anaesthetized rats. Auton Autacoid Pharmacol 2009;29:43-50
48. Dogrul A, Seyrek M. Systemic morphine produce antinociception mediated by spinal 5-HT7, but not 5-HT1A and 5-HT2 receptors in the spinal cord. Br J Pharmacol 2009;149:498-505
49. Brenchat A, Romero L, Garc?́a M, et al. 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. Pain 2009;141:239-247
50. Diaz-Reval MI, Ventura-Martinez R, Deciga-Campos M, et al. Evidence for a central mechanism of action of S-(+)- ketoprofen. Eur J Pharmacol 2004;483:241-248
51. Harte SE, Kender RG, Borszcz GS. Activation of 5-HT1A and 5-HT7 receptors in the parafascicular nucleus suppresses the affective reaction of rats to noxious stimulation. Pain 2005;113:405-415
52. Leopoldo M. Serotonin(7) receptors (5-HT7Rs) and their ligands. Curr Med Chem 2004;11:629-661
53. Pittalà V, Salerno L, Modica M, et al. 5-HT7 receptor ligands: recent developments and potential therapeutic applications. Mini Rev Med Chem 2007;7:945-960
54. Mitsubishi Pharma Corp. Compounds having 5-HT7 receptor antagonist activity and muscarinic M4 receptor agonist activity and their use in the treaatment of psychotic disorders. WO2004087124; 2004
55. Suckling CJ, Murphy JA, Khalaf AI, et al. M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: serominic compounds. Bioorg Med Chem Lett 2007;17:2649-2655
56. University of Bari. N-(1,2,3,4- tetrahydronaphthalen-1-yl)-4-phenyl-1- piperazinealkylamide derivatives, and therapeutic use threof as 5-HT7 receptor ligands. US20070117811; 2007
57. Leopoldo M, Berardi F, Colabufo NA, et al. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1- yl)-4-aryl-1- piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. J Med Chem 2004;47:6616-6624
58. Leopoldo M, Lacivita E, Contino M, et al. Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1- yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem 2007;50:4214-4221
59. Pfizer Products, Inc. Quinoline derivatives. WO2004043929; 2004
60. Ajinomoto Co., Inc. Novel piperidine derivatives. WO2004103972; 2004
61. Merck & Co., Inc. Sulfone derivatives as 5-HT7 receptor ligands. US20040229864; 2004
62. Raubo P, Beer MS, Hunt PA, et al. Aminoalkyl phenyl sulfones-a novel series of 5-HT7 receptor ligands. Bioorg Med Chem Lett 2006;16:1255-1258
63. Egis Gyógyszergyár. Pyridine derivatives of alkyl oxindoles as 5HT7 receptor active agents. WO2005108388; 2005
64. Egisy Gyógyszergyár. Piperazine derivatives of alkyl oxindoles. WO2005108363; 2005
65. Volk B, Barkóczy J, Hegedus E, et al. Phenylpiperazinyl-butyl) oxindoles as selective 5-HT7 receptor antagonists. J Med Chem 2008;51:2522-2532
66. Egis Gyógyszergyár. New benzofuran derivatives as selective 5HT7 receptor inhibitors and process for their preparation. WO2008146064; 2008
67. Eli Lilly & Co. 2-[4-(Pyrazol-4-ylalkyl) piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl) piperazin-1-yl]-2-phenyl pyridines as 5-HT7 receptor antagonists. WO2008141020; 2008
68. Shibata M, Ohkubo T, Takahashi H, et al. Modified formalin test: characteristic biphasic pain response. Pain 1989;38:347-352
69. Tjølsen A, Berge OG, Hunskaar S, et al. The formalin test: an evaluation of the method. Pain 1992;51:5-17
70. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-363
71. Sethy VH, Oien TT. Role of cGMP in the mechanism of anxiolytic activity of U-78875. Pharmacol Biochem Behav 1991;39:379-382
72. Eli Lilly & Co. 5-HT7 receptor antagonists. WO2009048765; 2009
73. Eli Lilly & Co. Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists. WO2009029439; 2009
74. Laboratorios del Dr Esteve SA. Heterocyclic-substituted- tetrahydronaphthalen- amine derivatives, their preparation an use as medicaments. WO2008116663; 2008
75. Laboratorios del Dr Esteve SA. Heterocyclic substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands. WO2008095689; 2008
76. Sanin A, Brisander M, Rosqvist S, et al. 5-Aryl substituted (S)-2- (dimethylamino)-tetralins novel serotonin 5HT7 receptor ligands. Proceedings of the 14th Camerino-Noordwijkerhout symposium. Ongoing progress in the receptor chemistry, Italy; 2003. p. 27
77. Holmberg P, Sohn D, Leideborg R, et al. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists. J Med Chem 2004;47:3927-3930
78. Laboratorios del Dr Esteve SA. Indane-amine derivatives, their preparation and use as medicaments EP2011786; 2007
79. Laboratorios del Dr Esteve SA. Heterocyclyl-substituted-ethylaminophenyl derivatives, their preparation and use as medicaments. WO2008077625; 2008
80. Laboratorios del Dr Esteve SA. 5-HT7 receptor antagonists. WO2006018308; 2006
81. Laboratorios del Dr Esteve SA. 5-HT7 receptor antagonsits. US20060142321; 2006
82. Artigas F, Romero L, de Montigny C, et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996;19:378-383
83. Available from: http://www.pgxhealth. com/development/vilazodone.cfm [Last accessed 24 February 2010]
84. Abbas AI, Hedlund PB, Huang XP, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009;205:119-128
85. Ruat M, Traiffort E, Leurs R, et al. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci USA 1993;90:8547-8551